MAFLD-simplified Definition as an Optimized Risk Stratification Tool for Predicting Metabolic Outcomes

Ningbo No. 1 Hospital

Status: Completed

Conditions: Metabolic Associated Fatty Liver Disease

Treatments: Diagnostic Test: the differences of MAFLD and MAFLD-simplified definitions were compared in predicting metabolic diseases

Study type: Observational

Funder types: Other

Identifiers

NCT04761900

MAFLDS-1.0

Details and patient eligibility

About

Recently, a consensus was proposed by an international expert panel for the terminology changed from NAFLD to Metabolic associated fatty liver disease (MAFLD). The comprehensive criteria shift to a "positive" diagnosis. It helps to increase patient awareness and understanding of fatty liver (FL), for who has high-risk metabolic dysfunction. However, a more simplified and easily applicable definition is needed. It will have an impact on clinical practice, especially in developing countries.

Full description

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver diseases. It affects nearly 25% of the global population. Recently, a consensus was proposed by an international expert panel for the terminology changed from NAFLD to Metabolic associated fatty liver disease (MAFLD). The comprehensive criteria shift to a "positive" diagnosis. It helps to increase patient awareness and understanding of fatty liver (FL), for who has high-risk metabolic dysfunction. However, a more simplified and easily applicable definition is needed. It will have an impact on clinical practice, especially in developing countries. It may provide a better understanding of MAFLD, and optimize strategies for prevention of extrahepatic complications in clinical practice.

Enrollment: 3,372 patients

Sex: All

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• diagnosed ad fatty liver by ultrasound

Exclusion criteria

• Missing data on Ultrasound, blood glucose, BMI and metabolic status.

Trial design

3,372 participants in 3 patient groups

participants were followed for the incidence of T2DM in a cohort study

Description:

performed a cohort analysis for T2DM. For incident T2DM cases, calculate the follow-up time from the date of enrollment into our study to the date of T2DM diagnosis.

Treatment:

Diagnostic Test: the differences of MAFLD and MAFLD-simplified definitions were compared in predicting metabolic diseases

participants were followed for the incidence of hypertension in a cohort study

Description:

performed a cohort analysis for hypertension. For incident hypertension cases, calculate the follow-up time from the date of enrollment into our study to the date of hypertension diagnosis.

Treatment:

Diagnostic Test: the differences of MAFLD and MAFLD-simplified definitions were compared in predicting metabolic diseases

participants were followed for the incidence of carotid atherosclerotic plaque in a cohort study

Description:

performed a cohort analysis for carotid atherosclerotic plaque. For incident carotid atherosclerotic plaque cases, calculate the follow-up time from the date of enrollment into our study to the date of carotid atherosclerotic plaque diagnosis.

Treatment:

Diagnostic Test: the differences of MAFLD and MAFLD-simplified definitions were compared in predicting metabolic diseases